Literature DB >> 26751601

Influence of weight reduction on blood levels of C-reactive protein, tumor necrosis factor-α, interleukin-6, and oxylipins in obese subjects.

Katharina Möller1, Annika I Ostermann2, Katharina Rund2, Stefanie Thoms3, Cornelia Blume3, Frank Stahl3, Andreas Hahn1, Nils Helge Schebb4, Jan Philipp Schuchardt5.   

Abstract

INTRODUCTION: Obesity is associated with inflammation and weight reduction has been shown to influence the inflammatory process. Besides classic inflammatory markers, oxidized polyunsaturated fatty acid (PUFA) metabolites (oxylipins) are potent mediators of inflammation. Little is known about endogenous levels of oxylipins, e.g. hydroxy, epoxy and dihydroxy FA in obese subjects with persistent low-grade inflammation. We aimed to evaluate levels of inflammatory markers and blood oxylipins in obese subjects before and after weight reduction. SUBJECTS AND METHODS: In the present study, 42 obese (BMI 32.7 ± 0.22 kg/m(2)) men and women were classified in groups according to high-sensitivity C-reactive protein (hsCRP) levels (no inflammation<1mg/L; low-grade inflammation ≥ 3 mg/L). Subjects underwent an intervention for eight weeks, which consisted of two phases: (1) week 1 and 2: total replacement of three meals by a formula diet and (2) six week partial formula diet (replacement of 1-2 meals). Blood samples were taken prior and post intervention for analysis of plasma protein levels of hsCRP, tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). Plasma Levels of free (unesterified) hydroxy, epoxy, and dihydroxy FAs as well as several prostanoids were analyzed in plasma by means of LC-MS-based targeted metabolomics.
RESULTS: At baseline subjects with low-grade inflammation (hsCRP 8.95 ± 1.39 mg/L) showed significant higher levels of IL-6 (22.7 ± 1.15 ng/L) and TNF-α (17.4 ± 0.75 ng/L) compared to subjects with no inflammation (hsCRP: 0.69 ± 0.05 mg/L; IL-6: 15.9 ± 1.18 ng/L; TNF-α: 14.6 ± 0.80 ng/L). In both group's body weight was significantly reduced (p<0.001) after intervention (no inflammation group: -7.19 ± 0.86 kg, -7.3 ± 0.89%, p<0.001; low-grade inflammation group: -6.78 ± 0.87 kg, -6.7 ± 0.81%, p<0.001). Moreover, we observed significant decreases in levels of hsCRP (4.66 ± 0.64 mg/L; p=0.006), IL-6 (6.81 ± 1.15 ng/L; p<0.001) and TNF-α (6.09 ± 0.47 ng/L; p<0.001) in subjects with low-grade inflammation. Of 60 quantified oxylipins, 11 linoleic acid (LA)-, 1 dihomo-γ-linolenic acid (DGLA)-, 7 alpha linolenic acid (ALA)-, 15 arachidonic acid (AA)-, 8 eicosapentaenoic acid (EPA)- and 18 docosahexaenoic acid (DHA)-metabolites could be detected in plasma. For most oxylipins no differences were found between the low and high hsCRP groups before and after weight reduction. Interestingly, in subjects with low- grade inflammation several AA-derived oxylipins (5-, 8-, 12-hydroxyeicosatetraenoic acids (HETE)) were significantly higher compared to subjects with no inflammation before weight reduction and significantly reduced after weight reduction.
CONCLUSION: Even moderate weight loss in obese subjects correlates to a significant improvement in the inflammatory state, by reducing hsCRP, IL-6, TNF-α and few oxylipins. The biological consequences of these changes remain to be further investigated.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Inflammation; Obesity; Oxylipins; PUFA; Weight loss

Mesh:

Substances:

Year:  2015        PMID: 26751601     DOI: 10.1016/j.plefa.2015.12.001

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  13 in total

1.  Profiling of Endogenous and Gut Microbial Metabolites to Indicate Metabotype-Specific Dietary Responses: A Systematic Review.

Authors:  Stefania Noerman; Marjukka Kolehmainen; Kati Hanhineva
Journal:  Adv Nutr       Date:  2020-09-01       Impact factor: 8.701

Review 2.  The possible factors affecting microglial activation in cases of obesity with cognitive dysfunction.

Authors:  Titikorn Chunchai; Nipon Chattipakorn; Siriporn C Chattipakorn
Journal:  Metab Brain Dis       Date:  2017-11-21       Impact factor: 3.584

Review 3.  Role of oxylipins in cardiovascular diseases.

Authors:  Mohammed A Nayeem
Journal:  Acta Pharmacol Sin       Date:  2018-06-07       Impact factor: 6.150

4.  Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment.

Authors:  Mark A Espeland; José A Luchsinger; Laura D Baker; Rebecca Neiberg; Steven E Kahn; Steven E Arnold; Rena R Wing; George L Blackburn; George Bray; Mary Evans; Helen P Hazuda; Robert W Jeffery; Valerie M Wilson; Jeanne M Clark; Mace Coday; Kathryn Demos-McDermott; John P Foreyt; Frank Greenway; James O Hill; Edward S Horton; John M Jakicic; Karen C Johnson; William C Knowler; Cora E Lewis; David M Nathan; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; Thomas A Wadden; Stephen R Rapp
Journal:  Neurology       Date:  2017-04-26       Impact factor: 9.910

Review 5.  Obesity: systemic and pulmonary complications, biochemical abnormalities, and impairment of lung function.

Authors:  Thiago Thomaz Mafort; Rogério Rufino; Cláudia Henrique Costa; Agnaldo José Lopes
Journal:  Multidiscip Respir Med       Date:  2016-07-12

Review 6.  Potential Impact of Nutrition on Immune System Recovery from Heavy Exertion: A Metabolomics Perspective.

Authors:  David C Nieman; Susan Hazels Mitmesser
Journal:  Nutrients       Date:  2017-05-18       Impact factor: 5.717

7.  Modified lingguizhugan decoction incorporated with dietary restriction and exercise ameliorates hyperglycemia, hyperlipidemia and hypertension in a rat model of the metabolic syndrome.

Authors:  Limei Yao; Jingjing Wei; Si Shi; Kunbin Guo; Xiangyu Wang; Qi Wang; Dingsheng Chen; Weirong Li
Journal:  BMC Complement Altern Med       Date:  2017-02-28       Impact factor: 3.659

8.  Obesity-induced changes in lipid mediators persist after weight loss.

Authors:  A Hernandez-Carretero; N Weber; M R La Frano; W Ying; J Lantero Rodriguez; D D Sears; V Wallenius; E Börgeson; J W Newman; O Osborn
Journal:  Int J Obes (Lond)       Date:  2017-11-01       Impact factor: 5.095

9.  Permissive underfeeding, cytokine profiles and outcomes in critically ill patients.

Authors:  Yaseen Arabi; Dunia Jawdat; Abderrezak Bouchama; Hani Tamim; Waleed Tamimi; Mohammed Al-Balwi; Hasan M Al-Dorzi; Musharaf Sadat; Lara Afesh; Mashan L Abdullah; Walid Mashaqbeh; Maram Sakhija; Mohamed A Hussein; Adila ElObeid; Abdulaziz Al-Dawood
Journal:  PLoS One       Date:  2019-01-07       Impact factor: 3.240

10.  Actions of annatto-extracted tocotrienol supplementation on obese postmenopausal women: study protocol for a double-blinded, placebo-controlled, randomised trial.

Authors:  Amir Aryaie; Grant Tinsley; Jaehoon Lee; Bruce A Watkins; Lane Moore; Adel Alhaj-Saleh; Kartik Shankar; Sarah R Wood; Rui Wang; Chwan-Li Shen
Journal:  BMJ Open       Date:  2020-03-08       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.